Biozen Named People's Choice Winner at ACC 2026 Innovation Pitch Challenge

Recognized at the American College of Cardiology Scientific Sessions for advancing cuffless blood pressure measurement

OKLAHOMA CITY, April 1, 2026 /PRNewswire/ -- Biozen, LLC has been named the 2026 People's Choice Winner of the American College of Cardiology (ACC) Future Hub Innovation Pitch Challenge, held March 29 during the ACC Scientific Sessions in New Orleans.

Being selected as the People's Choice Winner reflects recognition from ACC attendees, highlighting Biozen's approach among a global field of emerging cardiovascular technologies.

Biozen presented its cuffless blood pressure technology, designed to measure absolute blood pressure without the need for a cuff or calibration.

Using proprietary pressure and optical sensing in conjunction with physiologically-informed algorithms, Biozen's ultra-compact BP1000 device, coupled with a companion app, directly measures blood pressure from the digital artery at the fingertip.

By capturing pressure at arterial occlusion, the BP1000 delivers an absolute blood pressure measurement grounded in established physiological principles and evaluated prospectively against the clinical gold standard.

"Being named the People's Choice Winner at ACC is a significant moment for our team," said Dikran Tourian, Chief Executive Officer of Biozen. "It reflects a growing focus on how blood pressure is measured and monitored, and the importance of building solutions that clinicians and consumers can trust."

"ACC's Future Hub brings forward technologies that are improving existing approaches to cardiovascular care," said Omer Inan, PhD, Chief Scientific Officer of Biozen. "Blood pressure measurement is one of the most important tools for preventative medicine, and we believe our technology will play a central role in expanding both screening and monitoring capabilities."

In addition to the Innovation Pitch Challenge, Biozen presented prospective clinical validation data at ACC evaluating its device under the ISO 81060-2:2018 validation protocol.

Biozen's presence at the American College of Cardiology Scientific Sessions and its selection as the People's Choice Winner reflect growing recognition of its approach to blood pressure measurement.

About Biozen
Biozen, LLC is a privately held digital health company headquartered in Oklahoma City, Oklahoma, with research and development in Atlanta, Georgia. Biozen's cuffless blood pressure platform, protected by more than 70 granted U.S. and international patents, integrates advanced biosensors with proprietary algorithms to deliver absolute, calibration-free blood pressure readings from the fingertip.

Note: The Biozen BP Sensor and BP1000 are investigational devices and are not yet cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.

To learn more, visit biozen.com.

Media Contact
Ashley Wilson
+1 405-413-5201
[email protected]

SOURCE Biozen, LLC